COVID-19 vaccines and investment markets

January 29 |  3 min read

While daily increases in COVID-19 cases in many countries have increased sharply over recent months, global equity markets have generally risen and, in some cases, made record highs. Why have equity markets risen? A key factor is the expectation that vaccines for COVID-19 will allow activity to increase materially, particularly in those industries where social interaction is high (e.g. leisure and entertainment). Given their importance for markets, this article briefly discusses recent vaccine developments.

Soon after COVID-19 became a significant issue for the world the search for a vaccine began. While it has taken many years to develop vaccines, progress in relation to COVID-19 has been considerably faster. This reflects the amount of resources that have been applied to this problem and significant advances in biotechnology in recent years.

Since December 2020, several vaccines have been approved in some countries. These include the following:

  • The BioNtech/Pfizer vaccine has a quoted 95% efficacy, according to Phase 3 trial data. It involves two doses and requires super chilled conditions, which can limit its distribution.
  • The Moderna vaccine has a quoted 94% efficacy, according to Phase 3 trial data. It involves two doses and requires super cold storage for transportation.
  • The AstraZenica/Oxford University vaccine has a 70% average efficacy rate according to phase three trial data. Cold, but not super-cold, storage is required for this vaccine.

Vaccines are now being deployed globally, with a focus on those people most exposed to the virus and those more susceptible to experiencing major virus-related issues (e.g. the elderly or people with pre-existing conditions). It will take several months before some of the benefits of vaccinations are evident. This is because the proportion of the world’s population that has been vaccinated is currently less than 1% and deployment takes time.

Developed world countries are expected to receive a high proportion of the vaccines that are available in 2021 as they have contracts with the vaccine suppliers. It is generally expected that around half of the US population will be vaccinated by mid-2021, with Australia likely to achieve that outcome in the second half of this year.

In summary, we have moved into a different phase of the COVID-19 environment, where vaccines are being deployed. This is expected to progressively reduce the number of virus cases and allow a relaxation of restrictions that have dampened the level of economic activity. While vaccines are a very positive development, there are risks. A key risk is that the virus mutates in a manner that materially reduces the effectiveness of vaccines. Another risk is that the immunity conferred by the vaccine wears off in a relatively short time period (a year or two). We expect that virus and vaccine developments, including second generation vaccines, will be an important influence on markets in 2021. Advances in the treatment of severe cases of COVID-19 have lagged behind the progress on vaccines. Progress towards effective treatments for severe cases will also influence markets this year.

January 29 |  3 min read

Must Reads

Feature, Fund news, Investments, must read  |  8 min read

US Inflation

It has been over a year since COVID-19 ended one of the longest equity bull markets in US history. Governments and central banks responded quickly and, as a result, global equity markets have not only recovered but some have hit record highs.

Feature, Fund news, Investments, must read  |  2 min read

Investment update March 2021

Auction clearance rates have recently reached elevated levels and this has coincided with very strong growth in house prices across Australian capital cities.

Feature, Fund news, Investments, must read  |  2 min read

Investment update October 2020

The global pandemic has created heightened levels of concern around asset valuations, especially for infrastructure and property assets.

Feature, Fund news, Investments, must read  |  3 min read

Investment update Sept 2020

September saw positive returns as investors continue to adjust to the ‘new normal’ of the Covid-19 affected world.

Build a better future for you and your family

Invest in your future self

Sustainable products, quality advice, education and of course, low fees.

You have options when it comes to saving in your super and drawing from it on retirement. Find out which of our retirement products is most suited to you.

The Latest

General, Investments  |  4 min read

Portfolio defensiveness – Part 2

Diversified bonds is an asset class that typically provides defensiveness during unfavourable investment environments.

Feature, General, Investments  |  3 Min read

Portfolio defensiveness – Part 1

Vision Super has a wide range of multi-asset class investment options for members. When designing these options, one consideration is ensuring an appropriate level of defensiveness given the investment objectives of the option.

General  |  4 min

Investment Update – June 2021

Despite the uncertainties associated with Covid-19, most of our investment options have seen strong returns in 2020/21.

Already a Vision Super member?

The great news is you can now open your pension account online through the secure site.

Not a Vision Super member?

You’ll just need to open a Vision Personal account first and then you can transfer across to a Vision Super pension.